Manidipino Normon (Manidipine Dihydrochloride)

Manidipine is a calcium channel blocker used to treat conditions related to elevated blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure, improving cardiovascular risk control.
• Primary hypertension: provides sustained blood pressure lowering when other agents are insufficient.
• Secondary hypertension (vascular tone component): assists in controlling pressure when caused by increased peripheral resistance.

• Manidipine selectively inhibits L-type calcium channels on vascular smooth‑muscle cells, preventing calcium influx that is necessary for contraction. This vasodilatory effect decreases peripheral vascular resistance, leading to a reduction in systemic arterial pressure without significant negative inotropic effects on the heart.

Manidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warm sensation, usually resolves with continued therapy.
• Peripheral edema: swelling of lower limbs, may require monitoring.
• Dizziness or light‑headedness: related to blood pressure lowering.
• Nausea: occasional gastrointestinal upset.
• Tachycardia: compensatory increase in heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, or airway, potentially life‑threatening.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Myocardial infarction: rare but reported in susceptible patients.
• Allergic reactions: rash, pruritus, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: assess baseline and periodic readings to avoid excessive hypotension.
• Liver function: evaluate hepatic enzymes, especially in patients with pre‑existing liver disease.
• Renal impairment: adjust therapy cautiously in moderate to severe renal dysfunction.
• Elderly patients: start at lower doses and monitor for dizziness or falls.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.
• Other antihypertensives (e.g., ACE inhibitors, ARBs): additive blood‑pressure‑lowering effect, risk of severe hypotension.
• Grapefruit juice: can elevate drug levels, leading to enhanced side effects.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate antihypertensive effect, requiring dose adjustment.
• Beta‑blockers: combined use can cause excessive heart‑rate reduction.
• NSAIDs: may attenuate antihypertensive response, necessitating closer blood‑pressure monitoring.